依达拉奉联合奥扎格雷钠治疗轻型缺血性卒中的疗效观察

Curative effect of Edaravone combined with Sodium Ozagrel in treatment of mild ischemic stroke

目的探讨依达拉奉联合奥扎格雷钠治疗轻型缺血性卒中的疗效。方法收集近两年本院诊断为轻型缺血性卒中的患者,随机分为研究组和对照组。两组基础治疗相同,对照组在基础治疗上加用依达拉奉治疗,研究组加用依达拉奉联合奥扎格雷钠治疗。比较:1两组入院时体重指数、空腹血糖、低密度脂蛋白、胆固醇水平;2两组治疗前后NIHSS评分及出院后1年卒中复发率。结果 1两组入院时体重指数、空腹血糖、低密度脂蛋白、胆固醇水平比较差异无统计学意义(P>0.05);2两组治疗前NIHSS评分比较差异无统计学意义(P>0.05),治疗后NIHSS评分及出院后1年卒中复发率比较差异有统计学意义(P<0.05)。结论依达拉奉联合奥扎格雷钠能够改善轻型缺血性卒中患者NIHSS评分,对减少复发有重要的价值。

Objective To evaluate the clinical efficacy of Edaravone combined with Sodium Ozagrel in the treatment of mild ischemic stroke. Methods Patients diagnosed as mild ischemic stroke from our hospital in last two years were randomly divided into study group and control group. The foundation treatment in the two groups was the same,the control group treated with Edaravone in treatment,the study group added with Edaravone combined with Sodium Ozagrel in the treatment. The body mass index,fasting blood glucose,low density lipoprotein cholesterol and cholesterol level were compared between the two groups at admission（ 1）.（ 2）NIHSS score of two groups before and after treatment and 1 year stroke recurrence rate after discharge. Results（ 1） there were no differences in body mass index（ BMI）,fasting blood glucose,low density lipoprotein cholesterol and cholesterol level between the two groups（ P〉0. 05）.（ 2） there were no differences in NIHSS scores between the two groups before treatment（ P〉0.05）; there were differences in the two groups after treatment（ NIHSS） and 1 year stroke recurrence rate after discharge（ P〈0.05）. Conclusions Edaravone combined with Sodium Ozagrel can improve NIHSS score in patients with mild ischemic stroke,and has important value to reduce the recurrence.